In-vitro activities of quinolones against mycobacteria

From the results of recently-published in-vitro studies, we have reviewed the activities of novel quinolones which are currently available, either commercially or for investigative purposes, against Mycobacterium tuberculosis, the atypical mycobacteria (principally the Mycobacterium avium complex, M...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antimicrobial chemotherapy 1993-12, Vol.32 (6), p.797-808
Main Authors: Garcia-Rodriguez, J. A., Garcia, A. C. Gomez
Format: Article
Language:English
Subjects:
Anti-Infective Agents - pharmacology
Antibacterial agents
Antibiotics. Antiinfectious agents. Antiparasitic agents
Biological and medical sciences
Ciprofloxacin - pharmacology
Humans
Medical sciences
Microbial Sensitivity Tests
Mycobacterium
Mycobacterium leprae - drug effects
Mycobacterium tuberculosis - drug effects
Nontuberculous Mycobacteria - classification
Nontuberculous Mycobacteria - drug effects
Norfloxacin - pharmacology
Ofloxacin - pharmacology
Pharmacology. Drug treatments
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:From the results of recently-published in-vitro studies, we have reviewed the activities of novel quinolones which are currently available, either commercially or for investigative purposes, against Mycobacterium tuberculosis, the atypical mycobacteria (principally the Mycobacterium avium complex, Mycobacterium chelonae, Mycobacterium xenopi, Mycobacterium marinum and Mycobacterium fortuitum) and Mycobacterium leprae. We have also evaluated the effects of the various methods for determining the susceptibilities of the mycobacteria on the in-vitro activities of these agents. Sparfloxacin, Win-57273, ciprofloxacin and ofloxacin were the most active agents overall. The in-vitro activities, efficacies in animal models, tissue and cell penetration and results of preliminary clinical investigations suggest that some of the newer quinolones might be effective alternatives to standard anti-tuberculous agents for the treatment of patients with infections caused by mycobacteria, particularly when there is resistance to the latter group of drugs.
ISSN:0305-7453
1460-2091
DOI:10.1093/jac/32.6.797